NASDAQ · Biotechnology · USD
Ernexa Therapeutics Inc. (ERNA) Stock Analysis
Ernexa Therapeutics Inc. (ERNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ERNA Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.19
- Previous Close
- $2.24
- Day's Range
- 2.08–2.26
- 52-Week Range
- 1.84–71.50
- Volume
- 8.50K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.65
Valuation
- Market Cap
- $3.44M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −13.63
Financials (FY)
- Revenue (FY)
- $0.00−100.00%
- Net Income (FY)
- −$14.08M
- Shares Outstanding
- 1.63M
- 1-Year Return
- −93.02%
Dividend and dates
- Avg Volume
- 54.53K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ERNA closed at $2.11, −93.02% over 1 year.
Ernexa Therapeutics Inc. (ERNA) has a market capitalization of $3.44M.
In fiscal 2025, ERNA reported revenue of $0.00.
ERNA Stock Return by Calendar Year
Ernexa Therapeutics Inc. (ERNA) 10-year return: what $10,000 became
- 1 year
- $10,000 $698
- −93.02%
- 5 years
- $10,000 $0.29
- −99.997%
- 10 years
- $10,000 $0.22
- −99.998%
If you had invested $10,000 in Ernexa Therapeutics Inc. (ERNA) 10 years ago, at the close on October 21, 2016, it would have been worth $0.22 at the close on October 21, 2026: −99.998% in total, −65.83% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −92.97% |
| 2025 | −72.41% |
| 2024 | −83.89% |
| 2023 | −44.10% |
| 2022 | −96.14% |
| 2021 | −6.92% |
| 2020 | +1.82% |
| 2019 | +12.82% |
| 2018 | −53.68% |
| 2017 | −50.47% |
| 2016 (partial year) | +60.68% |
As of October 21, 2026.
ERNA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$14.08M | — |
| 2024 | $582.00K | −$44.54M | −7,652.7% |
| 2023 | $68.00K | −$21.67M | −31,864.7% |
| 2022 | $0.00 | −$24.58M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | −$9.32M | −$14.08M | — |
| 2024 | $582.00K | $486.00K | −$17.25M | −$44.54M | −7,652.7% |
| 2023 | $68.00K | −$168.00K | −$20.68M | −$21.67M | −31,864.7% |
| 2022 | $0.00 | $0.00 | −$26.95M | −$24.58M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
YahooErnexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
YahooErnexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8
BenzingaErnexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
YahooErnexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
YahooErnexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine
Benzinga
All 10 articles ↓Show fewer ↑
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
YahooErnexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
YahooErnexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
YahooErnexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B